Literature DB >> 16437722

Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan.

Shih-Chao Kang1, Shinn-Jang Hwang, Shiang-Ho Lee, Full-Young Chang, Shou-Dong Lee.   

Abstract

AIM: To evaluate health-related quality of life (HRQOL) in Chinese patients with chronic hepatitis C (CH-C), and the impact of antiviral treatment.
METHODS: Short Form 36 (SF-36) Health-related Quality of Life Questionnaires to interview CH-C patients, and age- and sex-matched control subjects at outpatient clinics of a medical center in Taiwan were used. Data were transformed to scores for comparisons of eight major SF-36 domains. We also enrolled consecutive CH-C patients who completed one course of antiviral treatment (interferon alpha with ribavirin), and measured the HRQOL before, at the 12th wk of treatment, at the end of treatment, and at mo 6, after stopping the treatment to evaluate the impact of antiviral treatment.
RESULTS: A total of 371 outpatients were enrolled, including 182 with CH-C and 189 age- and sex-matched subjects without CH-C. CH-C subjects had obviously lower educational status (P<0.01). Mean scores of domains in general health, physical functioning, role-physical, role-emotional, vitality, and mental health of the SF-36 were significantly lower in subjects with CH-C than those without CH-C (P<0.05). In an analysis of 47 CH-C patients who received and completed the whole course of antiviral treatment, mean scores of all domains were significantly lower at wk 12 of treatment compared to baseline. The scores returned to pretreatment values by the end of treatment, but were significantly increased at mo 6 after stopping the treatment. Among the 47 CH-C patients, 21 had sustained responses and 26 had non-sustained responses to antiviral treatment. Compared to pretreatment values, subjects with sustained responses had significantly lower social functioning scores at wk 12 of treatment, and scores for all SF-36 domains returned to pretreatment values, and increased significantly at mo 6 after stopping the treatment. For non-sustained virological responders, scores of all SF-36 domains significantly decreased at wk 12 of treatment, and did not increase significantly by the end of treatment, or at mo 6 after stopping the treatment when compared to the pretreatment values.
CONCLUSION: HRQOL in CH-C patients is significantly impaired in most SF-36 domains. Antiviral treatment impaired HRQOL of CH-C subjects during early treatment, mainly in non-sustained virological responders, and improved at mo 6 after stopping the treatment, mainly in sustained virological responders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437722      PMCID: PMC4725183          DOI: 10.3748/wjg.v11.i47.7494

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

Authors:  H L Bonkovsky; J M Woolley
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

2.  The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  J E Ware; M Kosinski; B Gandek; N K Aaronson; G Apolone; P Bech; J Brazier; M Bullinger; S Kaasa; A Leplège; L Prieto; M Sullivan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

3.  Use of structural equation modeling to test the construct validity of the SF-36 Health Survey in ten countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  S D Keller; J E Ware; P M Bentler; N K Aaronson; J Alonso; G Apolone; J B Bjorner; J Brazier; M Bullinger; S Kaasa; A Leplège; M Sullivan; B Gandek
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

4.  Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

Authors:  J E Ware; B Gandek
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

5.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.

Authors:  Felicitas C Kuehne; Ullrich Bethe; Kenneth Freedberg; Sue J Goldie
Journal:  Arch Intern Med       Date:  2002 Dec 9-23

8.  The prevalence and risk factors analysis of serum antibody to hepatitis C virus in the elders in northeast Taiwan.

Authors:  Cheng-Ching Lin; Shinn-Jang Hwang; Shu-Ti Chiou; Chin-Lan Kuan; Luke Wen-Tsuei Chen; Tai-Chi Lee; Ming-Bin Lee; Hsiang-Ho Lee; Pi-Shan Hsu; Shih-Tzu Tsai
Journal:  J Chin Med Assoc       Date:  2003-02       Impact factor: 2.743

9.  Mixed infections of hepatitis C virus as a factor in acute exacerbations of chronic type C hepatitis.

Authors:  J H Kao; P J Chen; M Y Lai; P M Yang; J C Sheu; T H Wang; D S Chen
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

10.  Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.

Authors:  S J Hwang; C Y Chan; R H Lu; J C Wu; S D Lee
Journal:  J Interferon Cytokine Res       Date:  1995-07       Impact factor: 2.607

View more
  14 in total

1.  Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment.

Authors:  Mitsuyuki Suzuki; Toru Ishikawa; Ai Sakuma; Satoshi Abe; Hiroko Abe; Fujiko Koyama; Tomomi Nakano; Aya Ueki; Hirohito Noguchi; Erina Hasegawa; Shiori Yamagata; Miki Kobayashi; Kazutaka Ohashi; Hiroshi Hirosawa; Takako Fukazawa; Yuka Maruyama; Toshiaki Yoshida
Journal:  Exp Ther Med       Date:  2016-10-05       Impact factor: 2.447

2.  Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument.

Authors:  Roger T Anderson; Robert W Baran; Birgitta Dietz; Eric Kallwitz; Pennifer Erickson; Dennis A Revicki
Journal:  Qual Life Res       Date:  2013-09-05       Impact factor: 4.147

Review 3.  Extrahepatic manifestations of chronic hepatitis C virus infection.

Authors:  Patrice Cacoub; Cloe Comarmond; Fanny Domont; Léa Savey; Anne C Desbois; David Saadoun
Journal:  Ther Adv Infect Dis       Date:  2016-02

4.  Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.

Authors:  K K Snow; H L Bonkovsky; R J Fontana; H-Y Kim; R K Sterling; A M Di Bisceglie; T R Morgan; J L Dienstag; M G Ghany
Journal:  Aliment Pharmacol Ther       Date:  2010-01-12       Impact factor: 8.171

5.  The effect of education on quality of life in patients under interferon therapy.

Authors:  Ahmad Ali Asadi Noghabi; Mitra Zandi; Abbas Mehran; Seyed Moayed Alavian; Ali Hasanpour Dehkordi
Journal:  Hepat Mon       Date:  2010-09-01       Impact factor: 0.660

6.  Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls.

Authors:  Guihua Zhuang; Min Zhang; Yong Liu; Yaling Guo; Qian Wu; Kaina Zhou; Zhenhao Ji; Xiaomei Zhang
Journal:  Health Qual Life Outcomes       Date:  2014-06-14       Impact factor: 3.186

7.  Health-related quality of life of Southern Chinese with chronic hepatitis B infection.

Authors:  Elegance T P Lam; Cindy L K Lam; C L Lai; M F Yuen; Daniel Y T Fong; Thomas M K So
Journal:  Health Qual Life Outcomes       Date:  2009-06-05       Impact factor: 3.186

8.  Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey.

Authors:  Marco Dacosta Dibonaventura; Yong Yuan; Benedicte Lescrauwaet; Gilbert L'italien; Gordon G Liu; Isao Kamae; Josephine A Mauskopf
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

9.  Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ.

Authors:  Shu-Chuan Chang; Sheng-Shun Yang; Chiu-Chun Chang; Chun-Che Lin; Yueh-Chin Chung; Tsai-Chung Li
Journal:  Health Qual Life Outcomes       Date:  2014-06-18       Impact factor: 3.186

10.  Translational research of telecare for the treatment of hepatitis C.

Authors:  Wan-Lin Chen; Wen-Ta Chiu; Ming-Shun Wu; Mei-Huang Hsu; Shin-Han Tsai
Journal:  Biomed Res Int       Date:  2014-06-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.